Acitve Recombinant Human TNFSF14 protein(Asp74-Val240), rFc-tagged

• Cat.No.: TNFSF14-1324H
• Product Overview: Recombinant Human TNFSF14 (AAK26160.1) (Asp74-Val240) was expressed in HEK293 with the Fc region of rabbit IgG at the N-terminus..

Specification

• Source: HEK293
• Species: Human
• Tag: N-rFc
• Protein length: Asp74-Val240
• Form: Lyophilized from sterile 50 mM Tris, 100 mM NaCl, pH 8.5. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Bio-activity: Measured in a cell prolifeRation assay using Human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 5-25 ng/mL.
• Molecular Mass: The recombinant Human TNFSF14 consists of 418 amino acids and predicts a molecular mass of 45.7 kDa.
• Endotoxin: < 1.0 EU per μg protein as determined by the LAL method.
• Purity: > 90 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 [ Homo sapiens ]
• Official Symbol: TNFSF14
• Synonyms: TNFSF14; tumor necrosis factor (ligand) superfamily, member 14; tumor necrosis factor ligand superfamily member 14; CD258; HVEM L; LIGHT; LTg; delta transmembrane LIGHT; herpesvirus entry mediator A; herpesvirus entry mediator ligand; herpesvirus entry mediator-ligand; herpes virus entry mediator ligand; ligand for herpesvirus entry mediator; tumor necrosis factor receptor-like 2; tumor necrosis factor superfamily member LIGHT; TR2; HVEML
• Gene ID: 8740
• mRNA Refseq: NM_003807
• Protein Refseq: NP_003798
• MIM: 604520
• UniProt ID: O43557

Reviews

07/28/2020

The extended longevity of results gave us the confidence to delve deeper into complex biological processes.

08/01/2018

It was reassuring to know that the product's effects persisted, allowing for thorough and comprehensive research.

06/19/2016

The ability to obtain enduring results positively influenced the depth of our investigations.

Q&As

What are the primary changes induced by TNFSF14 in the tumor microenvironment?

TNFSF14, when delivered to or expressed within tumors, causes significant changes primarily through vascular normalization and generation of tertiary lymphoid structures.

What challenges remain in utilizing TNFSF14 for cancer immunotherapy?

While investigators have used multiple vectors to deliver TNFSF14 to tumor tissues, there are still improvements needed, and components within the human tumor microenvironment may impede translational efforts.

What does TNFSF14 stand for?

TNFSF14 stands for Tumor Necrosis Factor Superfamily Member 14.

How can TNFSF14 synergize with other immunotherapy modalities?

TNFSF14's changes in the tumor microenvironment can synergize with methods inducing anti-tumor immune responses, such as checkpoint inhibitors and tumor vaccines, improving immunotherapeutic strategies against cancer.

In what context has TNFSF14 been utilized to combat cancer?

TNFSF14 has been used in multiple tumor models, where it can be combined with other immunotherapy modalities to clear established solid tumors and treat metastatic events.

How long has TNFSF14 been in pre-clinical development?

TNFSF14 has been in pre-clinical development for over a decade.

What is the primary promise of TNFSF14 in the field of cancer immunotherapy?

TNFSF14 shows promise in enhancing treatment approaches in cancer immunotherapy.